Business Wire

Axonic Capital Hires Michael Gordon as Head of Insurance Solutions

Share

Axonic Capital, New York-based structured credit, commercial real estate, and systematic fixed income specialist with $4.8 billion in assets under management, announced the addition of Michael Gordon, who will build out Axonic’s Insurance Solutions business.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220802006037/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Michael Gordon - Head of Insurance Solutions at Axonic Capital (Photo: Business Wire)

Axonic’s Insurance Solutions business is focused on providing capital and investment solutions that match liabilities for the benefit of policyholders and other stakeholders. Mr. Gordon will be responsible for leading Axonic’s insurance investments, strategic partnerships, and other transactions with insurance companies.

Mr. Gordon has over two decades of experience predominantly focused within the insurance and investment management markets. Prior to joining Axonic Mr. Gordon was US Chief Executive Officer and Group Chief Operating Officer at Lombard International.

“We are pleased to welcome Michael as a key addition to our leadership team during a time of increasing growth for our business. He brings invaluable experience that will benefit our longstanding institutional investors and support the development of new partnership and investment opportunities as we further grow our insurance platform,” said Clay DeGiacinto, Chief Investment Officer and Managing Partner of Axonic.

“Axonic's platform is well built to service the current and future needs of insurance companies leveraging our extensive expertise across commercial real estate and structured credit. The Axonic Insurance Solutions Business will partner with leading insurers to develop portfolios with high-quality investments that generate attractive risk-adjusted returns for insurers, policyholders, beneficiaries and other stakeholders.”

Prior to joining Lombard International, Mr. Gordon served as the Global Head of Insurance Solutions at BNY Mellon Investment Management. Prior to BNY Mellon, he was an executive at New York Life Insurance Company, leading investment and insurance product management, including sales and marketing, actuarial, operational, and technology functions, as well as overseeing the Broker Dealer and the Registered Investment Advisor for the U.S. life insurance business.

Mr. Gordon earned his B.A. in Philosophy from Colgate University.

About Axonic Capital

Founded in 2010, Axonic Capital offers commercial and residential real estate strategies, systematic fixed income and commercial lending strategies along with its structured credit expertise. Axonic Capital manages investment portfolios across Limited Partnerships, Separate Accounts, and two publicly registered Funds. The firm employs 56 professionals.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Axonic Capital Media:
Melissa Parvis
+1 212 828 7209

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Dentalis Animal Health appoints Advisory Board4.2.2023 15:09:00 CET | Press release

Dentalis Animal Health, a company specializing in Oral Health care for companion animals, has announced the appointment of its Advisory Board. Michael Kelly Michael Kelly is an Animal Health Pharmaceutical Industry veteran with broad international business experience. A graduate of Harvard Business School and Cornell University, Michael was hired by Ciba-Geigy to begin his post graduate career in Switzerland. Eventually ending up in the Novartis Animal Health US Division (following the Ciba-Sandoz merger) he rose to CFO and VP of North America. In 2009 Kelly joined Piedmont Animal Health (PAH), a drug development company, and served various roles including CFO, COO and President. During his tenure at PAH the organization received more FDA Companion Animal Drug approvals than any other Company in the Industry. Dr Stephanie Livermore Dr. Stephanie Livermore has been practicing companion animal medicine and surgery since her graduation from the University of Guelph in 2008. Dr. Livermore

Autel Brings MaxiCharger DC Compact to eCarExpo and Signs Partnership Agreement with Leading Charging Operator Eways4.2.2023 09:00:00 CET | Press release

Autel, a leading provider of automotive electronics and diagnostic equipment and tools, exhibited for the first time at eCarExpo, the largest electric vehicles fair in the Nordic countries, on February 3-5, 2023, in Friends Arena, Stockholm. Autel brought its portfolio of products featuring the recently launched electric vehicle charger the MaxiCharger DC Compact. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230204005001/en/ Autel signs partnership agreement with leading charging operator Eways (Photo: Business Wire) As Autel's newly launched DC charger for EVs, the MaxiCharger DC Compact is not only sleek and compact with a 21.5-inch LCD touchscreen, but also powerful enough to provide up to 47kW of power for the European version. Either placed on a pedestal, or set on wheels for ultimate portability, the MaxiCharger DC Compact is perfect for charging operators wanting to provide their customers with a quick charge option

U.S. FDA Approves Takeda’s TAKHZYRO ® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older4.2.2023 00:48:00 CET | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the expanded use of TAKHZYRO® (lanadelumab-flyo) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in pediatric patients 2 to <12 years of age.1 Prior to today’s approval, the only approved routine prophylaxis treatment options for children 6 to <12 years of age required dosing every three to four days,and children with HAE 2 to <6 years of age had no approved prophylaxis treatment, making TAKHZYRO the first prophylaxis treatment for this age group.1-5 The recommended dose is 150 mg/1 mL solution in a single-dose prefilled syringe every four weeks in patients 2 to <6 years of age and every two weeks in patients 6 to <12 years of age.1 HAE attacks can involve serious and debilitating swelling in the abdomen, face, feet, genitals, hands and throat.5,7 Potentially fatal upper airway angioedema has been reported i

SLB Completes Acquisition of Gyrodata Incorporated3.2.2023 22:05:00 CET | Press release

SLB (NYSE: SLB) today announced it has completed the acquisition of Gyrodata Incorporated, a global company specializing in gyroscopic wellbore positioning and survey technology. The transaction will incorporate Gyrodata’s wellbore placement and surveying technologies within SLB’s Well Construction business, bringing customers innovative drilling solutions. This combination will improve wellbore quality and reduce drilling risk to unlock even the most remote and complex reservoirs. Integrating three-axis solid state gyro measurements with the latest SLB technological innovations will help ensure tighter trajectory control, reduce data acquisition time and improve the decision-making process—resulting in greater overall drilling efficiency. “I’m excited for this historic moment that will bring innovative solutions to the SLB Well Construction division and our industry,” said Jesus Lamas, president, Well Construction, SLB. “The technology-driven acquisition of Gyrodata is aligned with SL

Gallagher Re Joins ABIR and EY as 2023 Bermuda Risk Summit Headline Sponsors3.2.2023 16:17:00 CET | Press release

The Bermuda Business Development Agency (BDA) is pleased to announce that Gallagher Re has joined the Association of Bermuda Insurers and Reinsurers (ABIR) and EY as headline sponsors of the second annual Bermuda Risk Summit. Adam Schwebach, Executive Vice President, Gallagher Re, said, “Gallagher Re is proud to support the second Bermuda Risk Summit, an annual event that showcases the breadth and versatility of Bermuda’s globally significant risk market. This event serves as a timely opportunity to connect with industry leaders ahead of midyear renewals and we applaud the BDA for their efforts in making the Bermuda Risk Summit a success.” David Hart, BDA CEO, said, “We are just so excited to welcome Gallagher Re as our third and final headline sponsor, along with ABIR and EY. The theme of the 2023 Bermuda Risk Summit, being held from March 6-8, 2023, at the Hamilton Princess & Beach Club is ‘Innovation, Sustainability and Collaboration. We anticipate an even stronger attendance level

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom